
CASI Pharmaceuticals CASI
$ 0.99
-0.01%
Quarterly report 2022-Q3
added 11-14-2022
CASI Pharmaceuticals Accounts Payables 2011-2026 | CASI
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables CASI Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 4.79 M | 3.67 M | 5.11 M | 968 K | 2.09 M | 1.06 M | 884 K | 755 K | 402 K | 505 K | 453 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.11 M | 402 K | 1.88 M |
Quarterly Accounts Payables CASI Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 3.1 M | 4.6 M | 7.17 M | 4.79 M | 6.32 M | 5.52 M | 5.74 M | 3.26 M | 3.67 M | 3.67 M | 3.67 M | 5.11 M | 5.11 M | 5.11 M | 5.11 M | 968 K | 968 K | 968 K | 968 K | 2.09 M | 2.09 M | 2.09 M | 2.09 M | 1.06 M | 1.06 M | 1.06 M | 1.06 M | 884 K | 884 K | 884 K | 884 K | 755 K | 755 K | 755 K | 755 K | 402 K | 402 K | 402 K | 402 K | 505 K | 505 K | 505 K | 505 K | 453 K | 453 K | 453 K | 453 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.17 M | 402 K | 2.14 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
13.4 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
601 K | - | 4.01 % | $ 150 M | ||
|
Adagene
ADAG
|
4.24 M | $ 2.75 | -5.5 % | $ 155 M | ||
|
ARCA biopharma
ABIO
|
3.46 M | - | 1052.0 % | $ 415 M | ||
|
Albireo Pharma
ALBO
|
6.52 M | - | -0.23 % | $ 916 M | ||
|
ANI Pharmaceuticals
ANIP
|
45.7 M | $ 81.6 | -0.49 % | $ 1.58 B | ||
|
Amgen
AMGN
|
1.91 B | $ 342.65 | -0.08 % | $ 184 B | ||
|
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | ||
|
Aytu BioScience
AYTU
|
10.6 M | $ 2.63 | 1.74 % | $ 16.5 M | ||
|
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | ||
|
Allena Pharmaceuticals
ALNA
|
1.03 M | - | 3.16 % | $ 1.9 M | ||
|
AVROBIO
AVRO
|
27 K | - | 1083.1 % | $ 745 M | ||
|
Aptose Biosciences
APTO
|
1.26 M | - | -45.71 % | $ 1.2 M | ||
|
Aravive
ARAV
|
8.76 M | - | -13.39 % | $ 1.45 M | ||
|
Biogen
BIIB
|
424 M | $ 178.24 | 1.2 % | $ 26 B | ||
|
Brickell Biotech
BBI
|
406 K | - | -5.38 % | $ 6.06 M | ||
|
Applied Molecular Transport
AMTI
|
1.58 M | - | - | $ 10.1 M | ||
|
Beam Therapeutics
BEAM
|
3.87 M | $ 27.94 | -4.61 % | $ 2.3 B | ||
|
Athira Pharma
ATHA
|
319 K | - | - | $ 269 M | ||
|
Atreca
BCEL
|
1.74 M | - | -11.76 % | $ 5.79 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
17.7 M | $ 70.74 | 2.34 % | $ 9.46 B | ||
|
AgeX Therapeutics
AGE
|
1.41 M | - | -10.17 % | $ 12.2 K | ||
|
Catalyst Biosciences
CBIO
|
355 K | $ 9.63 | -5.08 % | $ 634 M | ||
|
Akouos
AKUS
|
1.28 M | - | 0.23 % | $ 488 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
486 K | - | -9.72 % | $ 5.89 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
8.13 M | - | -15.15 % | $ 60.3 M | ||
|
Berkeley Lights
BLI
|
10.1 M | - | -7.31 % | $ 87 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 4.05 | -1.22 % | $ 8.81 B | ||
|
Amneal Pharmaceuticals
AMRX
|
153 M | $ 13.65 | -3.3 % | $ 4.22 B | ||
|
Bellerophon Therapeutics
BLPH
|
1.23 M | - | -74.18 % | $ 955 K | ||
|
Cerus Corporation
CERS
|
21.7 M | $ 2.32 | -0.22 % | $ 428 M | ||
|
Acer Therapeutics
ACER
|
3.81 M | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
4.29 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
247 K | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
750 K | - | -11.43 % | $ 502 K | ||
|
Baudax Bio
BXRX
|
3.93 M | - | 0.59 % | $ 63 K |